The race to build a biotechnology company capable of extending human lifespan is underway.
What’s happening:
- Hevolution Foundation has announced they have led a $50 million Series A financing round for longevity biotechnology company Aeovian Pharmaceuticals
- The round also saw notable participation from Apollo Health Ventures, Sofinnova Investments, Evotec and others
The big idea:
- Aeovian is developing novel therapeutic compounds that target highly selective small molecules to restore cellular metabolic quality
- The therapeutics compounds being developed by Aeovian are aiming to combat the dysregulated growth and hyperactive signalling that is commonly found in rare genetic disease and age related diseases
Why it matters:
- Hevolution Foundation is one of the largest funding sources of longevity science globally, amidst a push from Saudi Arabia to become a leader in incubating longevity biotechnology companies
Going deeper:
- Aeovian Pharmaceuticals has also recently begun dosing patients in their first ever Phase I clinical trial for the treatment of seizures and Tuberous Sclerosis Complex
The intrigue:
- Longevity biotech startups focused on animal health have also been accelerating, with the notable launch of the first ever large scale clinical trial for extending the lifespan of dogs officially beginning to dose canines
